New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 20, 2014
10:53 EDTSLXP, AGN, VRXAnalysts say Salix takeover would boost Allergan
Acquiring Salix (SLXP) would be a positive move for Allergan (AGN), two research firms indicated in notes to investors today. WHAT'S NEW: After The Wall Street Journal yesterday reported that Allergan had approached Salix and at least one other drug maker about a possible takeover as it fends off Valeantís (VRX) hostile buyout attempt, William Blair analyst Tim Lugo wrote that a merger between Allergan and Salix would produce a "very attractive" combined company. Salix would provide Allergan with significant growth, according to Lugo. The regulatory risk of Salix's treatment for Iiritable bowel syndrome with diarrhea has been reduced as a result of positive data on the drug, the analyst stated. Moreover, a combination of Allergan and Salix would have "more obvious value" next year than a combination of Allergan and Valeant, Lugo believes. Salix provides more growth opportunities for Allergan than Valeant, Lugo wrote. Allergan could bid around $192 per share for Salix, according to the analyst, who kept Outperform ratings on both Allergan and Salix. Meanwhile, analysts at Wells Fargo believe that a largely debt financed acquisition of Salix by Allergan could boost Allergan's earnings by 8% in 2015 and 2016, and 11%-12% in 2017-2018. Including share repurchases, the deal could increase Allergan's 2016 earnings per share outlook to $11 from $10, the firm believes. PRICE ACTION: In mid-morning trading, following rallies yesterday, Salix fell 3.5% to $155 and Allergan lost 0.5% to $161.
News For AGN;SLXP;VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
March 16, 2015
10:18 EDTVRX, SLXPValeant should win Salix with increased offer, says Cantor
Subscribe for More Information
10:14 EDTAGNOptions with decreasing implied volatility
Options with decreasing implied volatility: EXPR ULTA SGMS QIHU BKS PAY URBN AGN AGNC
10:07 EDTSLXPHigh option volume stocks
Subscribe for More Information
09:24 EDTSLXPEndo withdraws proposal for Salix
Subscribe for More Information
09:22 EDTSLXP, VRXOn The Fly: Pre-market Movers
Subscribe for More Information
08:17 EDTSLXP, VRXValeant rises 1% after sweetening Salix takeover offer
Subscribe for More Information
08:06 EDTSLXP, VRXValeant ses Salix deal closing on April 1
08:05 EDTSLXP, VRXValeant raises offer price for Salix to $173 per share from $158
Subscribe for More Information
08:04 EDTSLXP, VRXValeant, Salix agree on amended terms to merger agreement
Subscribe for More Information
07:50 EDTSLXPSalix trading halted, pending news
Subscribe for More Information
07:50 EDTVRX, SLXPValeant to raise offer for Salix to $173 per share, DJ reports
Dow Jones cites sources.
March 13, 2015
15:50 EDTSLXP, VRXValeant announces HSR clearance for acquisition of Salix
Valeant Pharmaceuticals (VRX) announced that it has received early termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to its proposed acquisition of Salix Pharmaceuticals (SLXP). The expiration of the waiting period satisfies one of the conditions to consummate the tender offer and Valeant expects to be in the position to close the transaction on April 1.
13:46 EDTSLXP, VRXValeant to raise Salix bid above $160 per share after Endo entry, NYT says
In response to Endo (ENDP) making a rival bid for Salix (SLXP), Valeant Pharmaceuticals (VRX) now plans to team up with Bill Ackman's Pershing Square and other top shareholders to raises its bid for Salix to above $160 per share, all in cash, according to The New York Times, citing people briefed on the matter. The exact price of Valeantís raised offer was not yet known, the report stated. Salix shares are down about 1% to $168.88 in afternoon trading. Reference Link
13:43 EDTSLXP, VRXValeant seen hiking Salix bid above $160 per share cash, NYT says
Subscribe for More Information
10:51 EDTSLXPOptions with increasing implied volatility
Options with increasing implied volatility: PVA BBEP SLXP ENDP MYL BBBY TEVA ZTS
08:15 EDTVRXAckman says shares of Valeant 'very cheap'
Subscribe for More Information
08:14 EDTVRX, SLXPAckman says does not view Endo bid for Salix as credible
Subscribe for More Information
08:13 EDTVRX, SLXPAckman says Endo would be very highly levered with Salix deal
Bill Ackman of Pershing Square is speaking on CNBC.
08:11 EDTVRX, SLXPAckman says Valeant CEO will not overpay for Salix
Bill Ackman of Pershing Square is speaking on CNBC.
05:47 EDTSLXPStocks with implied volatility movement; SLXP MNKD
Stocks with implied volatility movement; Salix (SLXP) 20, Teva (TEVA) 27 according to iVolatility.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use